Correspondence and Brief Communications |

Treatment Considerations for Inherited Thrombophilia and Pulmonary Embolus

Robert J. Baker, MD
Arch Surg. 2001;136(2):237. doi:10.1001/archsurg.136.2.237.
Text Size: A A A
Published online


The article by Blaszyk and Björnsson1 in the December issue of the ARCHIVES is one of many recently published concerning the factor V Leiden (FVL) mutation. The "big three" of thrombophilias (hypercoagulability states) used to be antithrombin deficiency, deficiency of protein C, and deficiency of protein S. Antithrombin III inactivates clotting factors Xa and XIII; although most patients have an acquired deficit, approximately 1 in 1000 individuals in the United States have a congenital deficit with an identified genetic defect (an autosomal dominant). Likewise, protein C and S deficits are ordinarily acquired (commonly from vitamin K deficiency) but can be inherited; these factors interfere with blood clotting by blocking factors V and VIII in the intrinsic cascade. The fourth and most common inheritable thrombophilia is now the FVL mutation, which results in resistance to activated protein C with the potential for causing spontaneous intravascular clotting. This is manifested primarily as spontaneous venous thrombosis but can occasionally cause pulmonary embolus and, less commonly, arterial obstruction.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles

Users' Guides to the Medical Literature
Thromboembolism or Acute Pulmonary Embolism

Users' Guides to the Medical Literature
Table 9.2-3 Refuted Evidence From Observational Studiesa